NCM Capital Management LLC Acquires 238 Shares of Bristol-Myers Squibb (NYSE:BMY)

NCM Capital Management LLC grew its holdings in Bristol-Myers Squibb (NYSE:BMY) by 1.1% in the 4th quarter, HoldingsChannel reports. The firm owned 21,626 shares of the biopharmaceutical company’s stock after buying an additional 238 shares during the quarter. NCM Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,223,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Transce3nd LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $28,000. Fairway Wealth LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $34,000. Tacita Capital Inc purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $39,000. Finally, M Holdings Securities Inc. bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $39,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on BMY. UBS Group dropped their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a report on Friday, April 25th. Jefferies Financial Group cut their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $58.00.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.07% of the stock is owned by insiders.

Bristol-Myers Squibb Price Performance

BMY opened at $47.84 on Wednesday. The stock’s 50-day moving average price is $52.55 and its 200 day moving average price is $55.89. The firm has a market cap of $97.36 billion, a price-to-earnings ratio of -10.82, a PEG ratio of 2.07 and a beta of 0.39. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the previous year, the business earned ($4.40) EPS. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.18%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.